PubMed Health⌕ Search

Biomedical subjects

Y Q Yu

Publications and source records attributed to Y Q Yu.

At least 55 records · Page 3Linked to original sources
PubMed1989

Hepatocellular carcinoma: some aspects to improve long-term survival.

Sixty-six patients surviving over 5 years after resection of hepatocellular carcinoma (HCC) are investigated. Of them, subclinical stage amounted to 56.1% (37/66) and moderate stage to 43.9% (29/66). There were 35 cases with small HCC (less than or equal to 5 cm). Cirrhosis was present in 81.1% (54/66). Radical resection was performed in 98.5% (65/66) and palliative resection in 1.5% (1/66). Reoperation for subclinical recurrence and solitary pulmonary metastasis was done in 14 patients, and sequential resection of huge tumors, in three patients. By the end of June 1988, follow-up varied from 60 to 319 months (mean, 115 months); 80.3% of the patients (53/66) are still alive and free of disease; 19.7% (13/66) died with disease. The majority of long-term survivors have returned to their original work; some young patients got married after resection of small HCC 10 years ago, and some can even play football again. Some aspects to improve long-term survival are discussed.

Adult↗
PubMed1989

[Resection of hepatic hilar liver cancer].

From January 1970 to January 1987, hepatic hilar liver cancer (or central type of hepatic cancer) resection was done in 51 cases. The resection was often extremely difficult, and sometimes complete occlusion of the hepatic blood supply was needed when the tumor lied close to, or already invaded the great blood vessels. The 1-, 3-, and 5- year postoperative survival rates were 65.7%, 45.3%, and 38.8%, respectively, in contrast to 93.8%, 86.1%, and 80.1% (P less than 0.001) obtained in 51 cases of peripheral type liver cancer of similar tumor size during the same period. It is considered that the difficulty involved in the resection of such a cancer, the limited extent of resection, and the easy entrance of tumor cells into the blood stream may explain the poor prognosis.

Carcinoma, Hepatocellular↗
PubMed1988

Clinical evaluation of cryosurgery in the treatment of primary liver cancer. Report of 60 cases.

Cryosurgery with liquid nitrogen was employed for the treatment of 60 patients with primary liver cancer (PLC) at the Liver Cancer Research Unit, Zhong Shan Hospital, Shanghai Medical University, the People's Republic of China, from November 1973 to August 1987. Of 60 patients, subclinical stage amounted to 35% (21/60), moderate stage 55% (33/60) and late stage 10% (6/60). There were 21 cases with small PLC (less than or equal to 5 cm). The postoperative course was uneventful in all of the 60 patients. These was no operative mortality, and there was no complications such as rupture of tumor, secondary bleeding, bile leakage, or abdominal infection. The 1-year, 2-year, 3-year, 4-year, and 5-year survival rates were 51.7% (30/58), 33.9% (19/56), 20.8% (11/53), 15.6% (7/45), and 11.4% (5/44), respectively, for the whole series. Among the 21 patients with tumor nodules less than or equal to 5 cm in diameter, the 1-year, 2-year, 3-year, 4-year, and 5-year survival rates were 76.2% (16/21), 61.9% (13/21), 50.0% (9/18), 41.2% (7/17), and 37.5% (6/16), respectively. These results indicate that hepatic cryosurgery is a promising, safe, and simple treatment for neoplastic disease of liver. Cryosurgery with liquid nitrogen can be considered the surgery of choice for nonresectable PLC in patients without jaundice, ascites, and noncompensated liver function, and the whole tumor mass can be involved in the frozen area.

Carcinoma, Hepatocellular↗
PubMed1987

[Small hepatocellular carcinoma (HCC) and its remote outcome].

Comparative study of 92 cases of pathologically proven small HCC (less than or equal to 5 cm) and 787 clinical HCC treated and followed in Zhongshan Hospital from 1958 to 1984 demonstrated that: 1. Resection of small HCC is the best way for long survival, 26 of the 51 patients who survived for more than 5 years had had small HCC. 2. The increase of the 5 year survival rates from 1.7% (1958-1966) through 7.1% (1967-1975) to 22.6% (1976-1984) of the whole series is due to the increase of proportion of small HCC (0%, 7.2% and 15.1%) in the respective periods. 3. In comparison to clinical HCC, small HCC showed higher resection rate (28.7% vs 85.9%), lower operative mortality (9.7% vs 1.3%) and better 5 year survival (19.9% vs 70.3%). 4. Concepts of early detection, early diagnosis, surgical treatment, management of recurrence and metastasis, prognosis, natural history of HCC, early development of HCC, etc. may be changed basing on this study. Reoperation of subclinical recurrence after small HCC resection has improved the 5 year survival from 56.2% in 1981 to 70.3% in this study.

Carcinoma, Hepatocellular↗
PubMed1986

The changing role of surgery in the treatment of primary liver cancer.

For decades, the role of surgery in the treatment of primary liver cancer (PLC) was important but limited. However, a comparison of pathologically proven PLC during the three periods 1958-1966, 1967-1975, and 1976-1984 revealed that as a result of alpha fetoprotein (AFP) serosurvey, changing concepts in surgical oncology, and introduction of new surgical modalities, the role of surgery has become greater. The increasing proportion of subclinical PLC (0, 7.2, and 21.2%) has favored the increasing series resection rate (16.1, 34.7, and 39.6%) and palliative surgery (13.7, 17.0, and 29.8%). The results indicated that early resection, reoperation for subclinical recurrence, resection of huge PLC in stages, and combination of palliative surgery other than resection might be responsible for the increasing 5-year survival rate (1.7, 7.1, and 19.5%) in the entire series.

Adenoma, Bile Duct↗
PubMedDate not supplied

Evolution of surgery in the treatment of hepatocellular carcinoma from the 1950s to the 1990s.

In the 1950s, hepatic lobectomy for huge hepatocellular carcinoma (HCC) has benefited 5-10% of HCC patients; in the 1970s, limited resection for small HCC and reresection for recurrence have benefited another 5-10% HCC patients. Cytoreduction and sequential resection for unresectable HCC might be of benefit to a further 5-10% HCC patients in the 1990s. Analysis of 1,642 patients with pathologically proven HCC in 1959-1991 demonstrated that the series 5-year survival has increased from 3.0% (n = 136) in the 1960s, to 12.2% (n = 440) in the 1970s, to 40.2% (n = 1,066) in the 1980s, which was correlated to the increasing number of limited resections for small HCC, reresections for subclinical recurrence, and cytoreductions and sequential resections for portions of unresectable HCC. With the advances in early detection, multimodality treatment, and changing concepts in surgical oncology, the role of surgery in the treatment of HCC has increased.

Adolescent↗
PubMedDate not supplied

Experience with resection of segment VIII of liver for hepatocellular carcinoma.

Hepatic segment VIII is located at the dome of the right liver lobe, next to the intrahepatic inferior vena cava (IVC) and is situated between the right and the middle hepatic veins. Its close relation to the IVC inferior medially makes liver cancer resection in this particular segment extremely difficult and hazardous. A personal series of 32 cases of segment VIII resection for hepatocellular carcinoma performed during the period January 1970-May 1992 is being presented. Most resections could be performed with occlusion of the porta hepatis only but some cases required total hepatic vascular exclusion. Since segment VIII is surrounded by major vessels, the extent of resection is limited in this region. Furthermore, tumor cells are easily disseminated along the vascular route. The long-term results are far from ideal. One-, 3-, and 5-year survival rates were 93.33%, 57.14%, and 28.5%, respectively. However, eight patients in this series have survived 180, 168, 104, 78, 53, 43, 43, and 36 months, respectively, and some of them have returned to work. Therefore, despite the technical difficulties involved in segment VIII resection, it is still worthwhile adopting an aggressive operative approach to this group of patients.

Adult↗
PubMedDate not supplied

Microwave surgery in the treatment of hepatocellular carcinoma.

Microwave surgery was employed for the treatment of 50 patients with hepatocellular carcinoma (HCC) and liver cirrhosis, including hepatectomy in 46 patients and in situ coagulation of tumor in 4 patients. In the study, 2,450 MHz microwaves were generated and transmitted to a monopolar needle electrode. For hepatectomy, the needle electrode was inserted into the liver parenchyma to coagulate the liver tissue and this was repeated at 1 cm intervals along the line where incision is anticipated. For unresectable HCC, the needle electrode was directly inserted into HCC to coagulate the cancer in situ. The average amounts of blood loss and blood transfusion for 46 hepatectomies using microwave were 215 +/- 189 ml and 274 +/- 261 ml, respectively. Eighteen patients (39.1%) did not need blood transfusion. A significant lower volume of blood loss and blood transfusion was observed in comparison with 46 matched conventional hepatectomies, 652 +/- 1,008 ml and 841 +/- 878 ml, respectively, all being P < 0.01. There were no operative mortality and complications, such as delayed bleeding, bile leakage, and abdominal infection. These results indicate that microwave surgery can be utilized safely and effectively in the field of liver surgery.

Adult↗